trending Market Intelligence /marketintelligence/en/news-insights/trending/NdIOG5H6Uh57H1QRZtvnwg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

VBI's hepatitis B vaccine matches GSK's Engerix-B in late-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

VBI's hepatitis B vaccine matches GSK's Engerix-B in late-stage study

VBI Vaccines Inc. said its hepatitis B vaccine Sci-B-Vac performed as well as GlaxoSmithKline PLC's Engerix-B in producing an immune response in patients with the disease as part of a late-stage study.

For the main goal of the phase 3 study, named Constant, the Cambridge, Mass.-based biotech was assessing the lot-to-lot consistency for immune response, as measured by geometric mean concentration of antibodies across three independent, consecutively manufactured lots of Sci-B-Vac, four weeks after the third vaccination.

The study's secondary goal was a non-inferior immune response versus Engerix-B as measured by seroprotection rates — the percentage of patients that yield a positive reading for antibodies capable of preventing infection — for patients receiving the vaccines at day 196. Subjects vaccinated with Sci-B-Vac had 99.3% seroprotection rates compared to 94.8% for those who received Engerix-B.

VBI Vaccines expects to begin regulatory submissions for the vaccine in the U.S., Canada and Europe in the second half of the year.

The company's share price was up 11.76% to $1.52 as of 11:23 a.m. ET on Jan. 9.